Plasma Angiotensin‐Converting Enzyme as a Prioritized Candidate Target for Alzheimer's Disease: Evidence From Proteome‐Wide Mendelian Randomization and a Large Prospective Cohort Study
Journal of the American Heart Association · 03.11.2026 · 15 (21)
DOI: 10.1161/jaha.124.038766 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of the American Heart Association, erschienen am 03.11.2026. Verfasst von Peiyuan Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Council Integrative Epidemiology Unit Bristol Medical School, University of Bristol Bristol UK. Hauptthemen laut MEDLINE: Alzheimer Disease, Peptidyl-Dipeptidase A, Angiotensin-Converting Enzyme Inhibitors, Proteome. Die Arbeit nennt 73 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Background
We aimed to provide hypothesis‐generating evidence on druggable targets for Alzheimer's disease (AD) by integrating proteome‐wide Mendelian randomization (MR) with evidence from a conventional observational analysis of drug use in a large prospective cohort.
Methods
Proteome‐wide MR analysis was conducted to identify plasma proteins causally related to AD risk using the largest summary‐level data to date, followed by colocalization and multiomic validation analyses (on the gene expression, alternative splicing, and DNA methylation levels in blood and brain, respectively) to prioritize potential druggable targets. We also replicated our MR findings using additional genetic data and performed multivariable MR for the prioritized findings. Conventional observational analysis in UK Biobank, a large prospective cohort, was performed to provide further clinical implications, using active comparator to minimize confounding by indication.
Results
MR analysis identified 15 plasma proteins with putative causal effects on AD risk. Of them, inhibition of angiotensin‐converting enzyme was found to increase the risk of AD (odds ratio, 1.10 [95% CI, 1.08–1.14]), which was likely independent of blood pressure as suggested by multivariable MR. Observational analysis in UK Biobank showed a higher incidence (hazard ratio, 1.23 [95% CI, 1.00–1.50]) of AD among regular users of angiotensin‐converting enzyme inhibitors, compared with the active comparator angiotensin receptor blocker users.
Conclusions
Our genetic analyses prioritized angiotensin‐converting enzyme as a candidate target, and a conventional observational analysis in a large prospective cohort provided supportive evidence that regular angiotensin‐converting enzyme inhibitor use was associated with a higher AD risk, which needs further investigation with high‐quality real‐world evidence and clinical trials before being translated into practice changes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Research Council Integrative Epidemiology Unit Bristol Medical School, University of Bristol Bristol UK.
- Department of Endocrine and Metabolic Diseases Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China.
- National Clinical Research Center for Metabolic Diseases (Shanghai), Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, National Research Center for Translational Medi…
- Population Health Sciences Bristol Medical School, University of Bristol Bristol UK.
- Clinical Research Center The Third Xiangya Hospital, Central South University Changsha Hunan China.
- Department of Metabolic and Bariatric Surgery The Third Xiangya Hospital, Central South University Changsha Hunan China.
ORCID-Profile: Peiyuan Huang, Haibo Tang, Tom R Gaunt, Jie Zheng, Yao Lu
Zitieren
APA
Huang, P., Tang, H., Feng, Z., Stergiakouli, E., Gaunt, T. R., Zheng, J., & Lu, Y. (2026). Plasma Angiotensin‐Converting Enzyme as a Prioritized Candidate Target for Alzheimer's Disease: Evidence From Proteome‐Wide Mendelian Randomization and a Large Prospective Cohort Study. Journal of the American Heart Association, 15(21). https://doi.org/10.1161/jaha.124.038766
Vancouver
Huang P, Tang H, Feng Z, Stergiakouli E, Gaunt TR, Zheng J, et al. Plasma Angiotensin‐Converting Enzyme as a Prioritized Candidate Target for Alzheimer's Disease: Evidence From Proteome‐Wide Mendelian Randomization and a Large Prospective Cohort Study. Journal of the American Heart Association. 2026;15(21). doi:10.1161/jaha.124.038766
BibTeX
@article{Huang2026,
author = {Huang, Peiyuan and Tang, Haibo and Feng, Zeying and Stergiakouli, Evie and Gaunt, Tom R and Zheng, Jie and Lu, Yao},
title = {Plasma Angiotensin‐Converting Enzyme as a Prioritized Candidate Target for Alzheimer's Disease: Evidence From Proteome‐Wide Mendelian Randomization and a Large Prospective Cohort Study},
journal = {Journal of the American Heart Association},
year = {2026},
volume = {15},
number = {21},
doi = {10.1161/jaha.124.038766}
}
EUVIMED